Psoriatic Arthritis

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
Atul A Deodhar, Bernard Combe, Ana P Accioly, Rebecca Bolce, Danting Zhu, Amanda M Gellett, Aubrey Trevelin Sprabery, Gerd-Rüdiger R Burmester

Annals of the Rheumatic Diseases Apr 2022, annrheumdis-2021-222027; DOI: 10.1136/annrheumdis-2021-222027
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Ingrid Egeland Christensen, Siri Lillegraven, Pawel Mielnik, Gunnstein Bakland, Liz Loli, Joe Sexton, Till Uhlig, Tore K Kvien, Sella A Provan

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 398-401; DOI: 10.1136/annrheumdis-2021-221007
Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index
Ilenia Pantano, Daniela Iacono, Ennio Giulio Favalli, Giuseppe Scalise, Luisa Costa, Francesco Caso, Giuliana Guggino, Raffaele Scarpa, Francesco Ciccia

Annals of the Rheumatic Diseases Mar 2022, 81 (3) e42; DOI: 10.1136/annrheumdis-2020-217251
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis
Maria Laura Acosta Felquer, Luciano LoGiudice, Maria Laura Galimberti, Javier Rosa, Luis Mazzuoccolo, Enrique R Soriano

Annals of the Rheumatic Diseases Jan 2022, 81 (1) 74-79; DOI: 10.1136/annrheumdis-2021-220865
Does biologic therapy impact the development of PsA among patients with psoriasis?
Elana Meer, Joseph F Merola, Robert Fitzsimmons, Thorvardur Jon Love, Shiyu Wang, Daniel Shin, Yong Chen, Sharon Xie, Hyon Choi, Yuqing Zhang, Jose U Scher, C T Ritchlin, Joel M Gelfand, Alexis Ogdie

Annals of the Rheumatic Diseases Jan 2022, 81 (1) 80-86; DOI: 10.1136/annrheumdis-2021-220761
Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells
Smriti K Raychaudhuri, Christine Abria, Siba P Raychaudhuri

Annals of the Rheumatic Diseases Jan 2022, 81 (1) e5; DOI: 10.1136/annrheumdis-2019-216658
Response to: ‘Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells’ by Raychaudhuri et al
Mary Canavan, Sarah M Wade, Douglas J Veale, Ursula Fearon

Annals of the Rheumatic Diseases Jan 2022, 81 (1) e6; DOI: 10.1136/annrheumdis-2019-216814
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Philip J Mease, Philip S Helliwell, Kasper Fjellhaugen Hjuler, Kyle Raymond, Iain McInnes

Annals of the Rheumatic Diseases Feb 2021, 80 (2) 185-193; DOI: 10.1136/annrheumdis-2019-216835
Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020
Olivier Lortholary, Mario Fernandez-Ruiz, John W Baddley, Oriol Manuel, Xavier Mariette, Kevin L Winthrop

Annals of the Rheumatic Diseases Dec 2020, 79 (12) 1532-1543; DOI: 10.1136/annrheumdis-2020-217092
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip Mease, Christina Charles-Schoeman, Stanley Cohen, Lara Fallon, John Woolcott, Huifeng Yun, Joel Kremer, Jeffrey Greenberg, Wendi Malley, Alina Onofrei, Keith S Kanik, Daniela Graham, Cunshan Wang, Carol Connell, Hernan Valdez, Manfred Hauben, Eric Hung, Ann Madsen, Thomas V Jones, Jeffrey R Curtis

Annals of the Rheumatic Diseases Nov 2020, 79 (11) 1400-1413; DOI: 10.1136/annrheumdis-2019-216761

Main menu

Psoriatic Arthritis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Psoriatic Arthritis

Pages